Ralf Gutzmer - Researcher Profile | RDL Research Database

Publications

2 shown

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont , Christian U. Blank , Mario Mandalà +26 more

As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free surviv...

2018 New England Journal of Medicine 1753 citations

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more

2015 The Lancet Oncology 2617 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,370
Institution: Medizinische Hochschule Hannover

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-7921-2820

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.